Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

A Study of AZD6738 in Combination With Durvalumab in Patients With Refractory Solid Tumors (Cohort A: Chemotherapy-Refractory Gastric Cancer; Cohort B: Anti-PD(L)

9 de noviembre de 2026 actualizado por: Jeeyun Lee, Samsung Medical Center

Estudio de fase II de AZD6738 en combinación con Durvalumab (MEDI4736), en pacientes con tumor sólido metastásico como tratamiento de rescate

This is a phase II, open-label study of AZD6738 in combination with durvalumab in patients with refractory solid tumors. The study includes three cohorts:

Cohort A (N=30): Patients with advanced gastric cancer who have progressed following second-line chemotherapy.

Cohort B (N=30): Patients with metastatic melanoma who have progressed following prior anti-PD(L)1 therapy.

Cohort C (N=30): Patients with advanced gastric cancer who have progressed following chemotherapy in combination with anti-PD(L)1 therapy.

Patients will receive AZD6738 plus durvalumab combination treatment.

For Cohorts A and B, AZD6738 will be administered at 240 mg twice daily on Days 15-28 of each 28-day cycle. Durvalumab will be administered at 1,500 mg every 4 weeks, starting on Cycle 1 Day 1.

For Cohort C, AZD6738 will be administered at 240 mg twice daily on Days 1-7 of each 28-day cycle. Durvalumab will be administered at 1,500 mg every 4 weeks, starting on Cycle 1 Day 8, following the initial 7-day AZD6738 treatment period.

Tumor evaluation using modified RECIST 1.1 will be conducted at screening (within 28 days before the first dose), every 8 weeks through Week 40, and every 12 weeks thereafter until objective disease progression, with an assessment window of ±7 days.

Patients will continue treatment until objective disease progression, unacceptable toxicity, or other protocol-defined discontinuation criteria are met. Treatment beyond disease progression may be permitted at the investigator's discretion if patients continue to derive clinical benefit and meet the protocol requirements. AZD6738 or durvalumab monotherapy is not permitted.

Tumor samples will be collected before treatment and at disease progression for exploratory biomarker analysis and investigation of resistance mechanisms. Rebiopsy may be waived if clinically infeasible, as specified in the protocol.

Descripción general del estudio

Estado

Activo, no reclutando

Intervención / Tratamiento

Descripción detallada

This is a phase II, open-label study evaluating the efficacy and safety of AZD6738 in combination with durvalumab in patients with refractory solid tumors.

Target Subject Population

The study includes three cohorts:

Cohort A: Patients with advanced gastric adenocarcinoma, including gastroesophageal junction cancer, who have progressed following second-line chemotherapy. Disease progression must be confirmed by imaging, with at least one measurable lesion according to modified RECIST 1.1.

Cohort B: Patients with metastatic melanoma who have progressed following prior anti-PD(L)1 therapy. Anti-PD(L)1 therapy must have been the immediate prior treatment regimen before study entry.

Cohort C: Patients with advanced gastric adenocarcinoma, including gastroesophageal junction cancer, who have progressed following chemotherapy in combination with anti-PD(L)1 therapy, with disease progression confirmed by imaging. Patients will receive AZD6738 in combination with durvalumab as third-line treatment.

Treatment Regimens

For Cohorts A and B, AZD6738 will be administered orally at 240 mg twice daily on Days 15-28 of each 28-day cycle. Durvalumab will be administered at 1,500 mg every 4 weeks, starting on Cycle 1 Day 1.

For Cohort C, AZD6738 will be administered orally at 240 mg twice daily on Days 1-7 of each 28-day cycle. Durvalumab will be administered at 1,500 mg every 4 weeks, starting on Cycle 1 Day 8.

Duration of Treatment

Patients will continue receiving AZD6738 and durvalumab as long as treatment is tolerable and clinical benefit is observed, as determined by the investigator.

Upon confirmed objective disease progression or fulfillment of other treatment discontinuation criteria, both AZD6738 and durvalumab must be discontinued. However, treatment beyond objective disease progression may be permitted at the investigator's discretion if the patient continues to derive clinical benefit and does not meet other discontinuation criteria.

If either AZD6738 or durvalumab must be permanently discontinued because of unacceptable toxicity, both agents must be discontinued. Patients are not permitted to continue either agent as monotherapy. There is no predefined maximum duration of combination treatment.

Tumor Assessment and Sample Collection

Tumor assessments will be performed using CT or MRI scans of the chest, abdomen, and pelvis according to modified RECIST 1.1. Assessments will be conducted at screening, every 8 weeks through Week 40, and every 12 weeks thereafter until objective disease progression.

Tumor samples from primary or metastatic lesions will be collected before treatment and at disease progression to support exploratory biomarker analyses and investigations of treatment resistance. Rebiopsy may be waived when clinically infeasible, in accordance with the protocol.

Tipo de estudio

Intervencionista

Inscripción (Actual)

91

Fase

  • Fase 2

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

      • Seoul, Corea del Sur, 06351
        • Samsung Medical Center

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

19 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  1. Provision of fully informed consent prior to any study specific procedures.

  2. Patients must be ≥ 18 years of age

  3. Patient with ATM deficient or ATM proficient through IHC. ATM expression status will be assessed prospectively. Minimum numbers of each patient group (ATM proficient and deficient) will be required for analysis, therefore central prospective screening will be deployed to ensure this is achieved.

  4. Body weight >30kg

  5. Cohort A: Confirmed histological or cytological diagnosis of gastric adenocarcinoma (including GEJ) that is at an advanced stage and that has progressed following who have failed secondary chemotherapy treatments (confirmed by imaging)

  6. Cohort B: Confirmed melanoma (metastatic) who has progressed to prior anti-PD(L)1 therapy (immediate prior regimen)

  7. Have the presence of measurable disease as defined by the Response Evaluation Criteria in Solid Tumors (modified RECIST) version 1.1 which is suitable for accurate repeated measurements.

  8. Provision of tumor sample (from either a resection or biopsy) for ATM IHC and other exploratory biomarker

  9. Patients are willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations.

  10. ECOG performance status 0-1 with no deterioration between screening and the first dose of study treatment

  11. Patients must have a life expectancy ≥ 3 months from proposed first dose date.

  12. Patients must have had a washout period of 3 weeks for any prior therapy prior to the start ot study drug. The following intervals between the end of the prior treatment and first dose of study drug must be observed: ≥ 4 weeks for radiotherapy (patients who receive palliative radiation for nontarget lesions need not have a 4 week washout period and can be enrolled immediately); patients may receive a stable dose of bisphosphonates or denusomab as long as these were started at least 4 weeks prior to treatment; ≥ 4 weeks for major surgery; ≥ 7 days for minor surgical procedures; ≥ 14 days (or 5 half lives whoever is longest) for any investigational product.

  13. Patients must have acceptable bone marrow, liver and renal function measured within 28 days prior to administration of study treatment as defined below:

    • Haemoglobin ≥9.0 g/dL (transfusion not permitted within 14 days of study medication)
    • Absolute neutrophil count (ANC) ≥ 1.5 x 109/L
    • INR ≥1.5 or evidence of impaired hepatic synthesis function
    • Platelet count ≥100 x 109/L (transfusion not permitted within 14 days of study medication
    • Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN)
    • AST (SGOT)/ALT (SGPT) ≤ 2.5 x institutional upper limit of normal unless liver metastases are present in which case it must be ≤ 5x ULN
    • Serum creatinine ≤1.5 x institutional ULN
    • Glomerular filtration rate < 45 mL/min as assessed by standard methodology at the investigating centre
    • Haematuria: +++ on microscopy or dipstick
  14. Female patients of childbearing potential must have a negative pregnancy test (urine or serum), must not be breastfeeding and using adequate contraceptive measures.

    Female patients must use a highly effective contraceptive measure from screening until 90 days after the last dose of drug. All methods of contraception (except for total abstinence) should be used in combination with the use of a condom by a male sexual partner for intercourse (see Restrictions below).

    Female patients must have evidence of non-childbearing potential by fulfilling one of the following criteria at screening:

    1. Post-menopausal women defined as aged more than 50 years and amenorrhoeic for at least 12 months following cessation of all exogenous hormonal treatment.
    2. Documentation of irreversible surgical sterilisation by hysterectomy, bilateral oophorectomy, or bilateral salpingectomy, but not tubal ligation.
    3. Amenorrhoeic for 12 months and serum follicle-stimulating hormone (FSH), lutenizing hormone (LH) and plasma oestradiol levels in the postmenopausal range for the institution
  15. For the duration of the study and for 1 week after the last study drug administration, sexually active male patients must be willing to use barrier contraception i.e. condoms with all sexual partners. Where the sexual partner is a 'women of child-bearing potential' who is not using effective contraception, men must use a condom (with spermicide) during the study and for 6 months after the last dose of a study drug.

  16. Mandatory biopsy during the screening window prior to dosing and at progression (fresh frozen will be mandatory if clinically feasible)

Exclusion Criteria:

  1. Diagnosis of ataxia telangiectasia.

  2. Any previous treatment with ATR inhibitors, DNA -damage repair inhibitors

  3. Any gastrointestinal condition that would preclude adequate abosrportion of AZD6738 including but not limited to inability to swallow oral medication, refractory nausea and vomiting, chronic gastrointestinal diseases or previous significant bowel resection, intestinal obstruction or CTCAE grade 3 or grade 4 upper GI bleeding within 4 weeks before the enrollment.

  4. Active or prior documented autoimmune or inflammatory disorders (including IBD[e.g. Chohn's disease, ulcerative colitis or diverticulitis], SLE, sarcoidosis syndrome, tuberculosis, Wegener syndrome, myasthenia gravis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, history of primary immunodeficiency or HIV infection, known hepatitis B or hepatitis C infection, history of organ transplant that requires use of immunosuppressives, glomerulonephritis, nephritic syndrome, Fanconi Syndrome or renal tubular acidosis within the past 2 years prior to the start of treatment. The following are exceptions to this criterion:

    • Subjects with vitiligo or alopecia, hypothyroidism (eg, following Hashimoto syndrome) stable on hormone replacement or psoriasis not requiring systemic treatment; patients with coeliac disease controlled by diet alone and patients without active disease in the last 5 years may be included after consultation with Chief Investigator.
  5. Cohort A: Confirmed histological or cytological diagnosis of gastric adenocarcinoma (including GEJ) that is at an advanced stage and has progressed following second-line chemotherapy (confirmed by imaging).

  6. Cohort B: Confirmed metastatic melanoma that has progressed following prior anti-PD(L)1 therapy. Anti-PD(L)1 therapy must have been the immediate prior treatment regimen before study entry.

  7. Cohort C: Confirmed histological or cytological diagnosis of gastric adenocarcinoma (including GEJ) that is at an advanced stage and has progressed following chemotherapy in combination with anti-PD(L)1 therapy (confirmed by imaging).

  8. Presence of measurable disease as defined by modified RECIST version 1.1, suitable for accurate repeated measurements.

  9. Receiving or having received, concomitant medications, herbal supplements, and/or foods that significantly modulate P450 3A4 (CYP3A4) or Pgp activity (washout periods of 5 half-lives). Note these include common azole antifungals, macrolide antibioics and other medications.

  10. Patient with any of the following cardiac criteria:

    • Mean QT interval corrected for heart rate (QTc) ≥ 470 ms calculated from 3 electrograms (ECGs) using Friderecia's correction
    • Any clinciallly important abnormalities in fhythm, conduction or morphology of resting ECG e.g. complete left bundle branch block , third degree heart block, second degree heart block.
    • Any factors that increae the risk of QTc prolongation or risk of arrhythmic events such as heart failure, hypokalaemia, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age or concomitant medication known to prolong the QT interval
    • Uncontrolled hypotension: systolic BP < 90 mmHg and/or diastolic BP 60 mmHg or clinically relvant orthostatic hypotension, including a fall in blood pressure of > 20 mmHg
    • Atrial fibrillation with a ventricular rate >100 bpm on ECG at rest
    • Symptomatic heart failure (NYHA grade II-IV)
    • Known reduced LVEF < 55%
    • Prior or current cardiomyopathy
    • Severe valvular heart disease
    • Uncontrolled angina (Canadian Cardiovascular Society grade II-IV despite medical therapy)
    • Stroke or transient ischaemic attack in the last 6 months prior to screening
    • Acute coronary syndrome within 6 months prior to starting treatment
  11. Ophthalmological conditions as follows:Intra-ocular pressure >21 mmHg, or uncontrolled glaucoma (irrespective of intra-ocular pressure), Current or past history of central serous retinopathy or retinal vein occlusion

  12. Any evidence of severe or uncontrolled systemic disease, including active infection (requiring antibiotics, antifungals or antivirals), diabetes type I and II, uncontrolled seizures, bleeding diatheses, severe COPD, severe Parkinson's disease.

  13. Any unresolved toxicity NCI CTCAE Grade ≥2 from previous anticancer therapy with the exception of alopecia, vitiligo, Major surgical procedure (as defined by the Investigator) within 28 days prior to the first dose of IP. Note: Local surgery of isolated lesions for palliative intent is acceptable.

  14. Female patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ effective birth control from screening to 90 days after the last dose of durvalumab monotherapy.

  15. Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: No aleatorizado
  • Modelo Intervencionista: Asignación de un solo grupo
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: GC

Patients with refractory gastric cancer who have failed secondary chemotherapy treatments for advanced disease will be enrolled. Patients must have imaging confirmed progression on previous chemotherapy for gastric cancer treatment with at least one measurable lesion per modified RECIST 1.1. GC patients must not have received previous therapy with immune checkpoint inhibitors. Prior exposure to AZD6738 is not allowed.

AZD6738 will be administered at 240 mg twice daily on days 1 to 7 in Cycle 0 (lead-in period) and therafter at 240 mg BD on days 22 to 28 in a 28-day cycle.

. Durvalumab will be administered at 1500 mg every 4 weeks from cycle 1 day 1.

Experimental: Melanoma

Patients with metastatic melanoma patients who have failed prior anti-PD(L)1 will be enrolled. Anti-PD(L)1 therapy should be the immediate prior regimen before study entry.

AZD6738 will be administered at 240 mg twice daily on days 1 to 7 in Cycle 0 (lead-in period) and therafter at 240 mg BD on days 22 to 28 in a 28-day cycle.

. Durvalumab will be administered at 1500 mg every 4 weeks from cycle 1 day 1.

Experimental: GC (Cohort C: ICI-Refractory)

Patients with refractory gastric adenocarcinoma (including gastroesophageal junction cancer) who have progressed following chemotherapy in combination with anti-PD(L)1 therapy for advanced disease will be enrolled. Disease progression must be confirmed by imaging, with at least one measurable lesion per modified RECIST 1.1.

Patients will receive AZD6738 in combination with durvalumab as third-line treatment. AZD6738 will be administered at 240 mg twice daily on Days 1-7 of each 28-day cycle. Durvalumab will be administered at 1,500 mg every 4 weeks, starting on Cycle 1 Day 8.

AZD6738 will be administered at 240 mg twice daily on days 1 to 7 in Cycle 0 (lead-in period) and therafter at 240 mg BD on days 22 to 28 in a 28-day cycle.

. Durvalumab will be administered at 1500 mg every 4 weeks from cycle 1 day 1.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
ORR
Periodo de tiempo: 2 years

Objective reponse rate (ORR) by modified RECIST 1.1

2 years

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

30 de julio de 2019

Finalización primaria (Estimado)

1 de diciembre de 2027

Finalización del estudio (Estimado)

1 de diciembre de 2027

Fechas de registro del estudio

Enviado por primera vez

18 de diciembre de 2018

Primero enviado que cumplió con los criterios de control de calidad

18 de diciembre de 2018

Publicado por primera vez (Actual)

19 de diciembre de 2018

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

13 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

9 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

INDECISO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir